Program
TCR1672
A development code. Also written as “TCR1672 tablet”.
In Sino Biopharmaceutical's pipeline, P2X3拮抗剂
. Its studies are mostly in Chronic Cough, led by Sino Biopharmaceutical.
Furthest: phase 2, since Dec 15, 20231 company-led study, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 11 open or running | phase 2since Dec 15, 2023 | Dec 15, 2023 | none ahead |
- Named in Sino Biopharmaceutical’s own pipeline as
TCR1672
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 15, 2023First study: phase 2 study in Chronic CoughFirst studyNCT06213363 · 72 planned
TargetBeta
“P2X3拮抗剂”the company's pipeline, read by Claude · source
Other programs on P2RX3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| camlipixant | GlaxoSmithKline | phase 3 | 16 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06213363Chronic Cough | 2 | Not yet recruiting | Oct 2024 | 72 |
How it is read
Names in the registry
- “TCR1672 tablet”, 1 entry
Codes read as this program: TCR1672.
Conditions, from the studies’ own filings
- Chronic Cough, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.